New heart drug AZD0233 begins first safety tests in healthy volunteers

NCT ID NCT06381466

Terminated Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested the safety of a new drug called AZD0233 in 84 healthy adults aged 18 to 50. The drug is being developed for dilated cardiomyopathy, a condition where the heart becomes enlarged and weak. Participants received either the drug or a placebo, and researchers monitored for side effects and how the drug moves through the body. The study was terminated, so its full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AZD0233
What this could lead to: If this early trial shows AZD0233 is safe, it could lead to further studies testing whether it helps control dilated cardiomyopathy.
What could go wrong: This is a very early Phase 1 trial in healthy people, not patients. The study was terminated, so results may be incomplete. Many early drugs never advance.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DILATED CARDIOMYOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dilated cardiomyopathy heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DILATED CARDIOMYOPATHY

Contacts and locations

Locations

Research Site

Glendale, California, 91206, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.